Integrated Silicon Solution, Inc.
Lumissil Microsystems introduce best-in-class automotive grade Green PHY solution
MILPITAS, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Lumissil Microsystems has announced its IS32CG5317, the world’s most advanced HomePlug Green PHY silicon solution for the Electric Vehicle (EV) market. IS32CG5317 is designed to meet the requirements of the EV charging systems and the commercial charger markets.
IS32CG5317 is a new modem designed with stringent automotive requirements in mind, from design to manufacturing. This highly integrated chip includes an analog front-end unit in a small EP-LQFP package. To support embedded applications, SPI and R/MII interfaces are available to enable direct connection to low cost microcontrollers commonly found in charging systems. To reduce the customer’s product cost, the use of an on board flash is optional. IS32CG5317 complies with HomePlug Green PHY and ISO/IEC 15118 specifications. Its development follows the automotive industry’s standards to meet AEC-Q100 grade 2 specification.
"Electric vehicle makers can finally design using best-in-class automotive grade Green PHY modem without worry of obsolesce," said Nadav Katsir, GM of the Connectivity Business Unit at Lumissil Microsystems.
"We are excited about the new Green PHY modem from Lumissil," said Mr. Andreas Tombuelt, Senior Manager of SW Development, Power Electronics, from KOSTAL.
"KOSTAL is one of the leaders in providing electric vehicle charging solutions, and with the growing demand for EV, we are focusing on improved solutions enabling automotive-qualified PLC communications. With the introduction of this new Automotive Green PHY modem, it increases the solutions available to address this market segment," Mr. Tombuelt stated.
Availability
IS32CG5317 will be available for customer evaluation in July 2021.
About Lumissil
Lumissil is the analog/mixed-signal product division of ISSI, a fabless semiconductor company that designs and markets high performance integrated circuits for the key markets of: (I) automotive, (ii) communications, (iii) industrial/medical devices, and (iv) digital consumer products. Lumissil’s products include LED drivers for low to mid-power RGB color mixing and high power lighting applications, audio, sensor, high-speed wired communications, optical networking ICs and application-specific microcontrollers. ISSI/Lumissil is headquartered in Silicon Valley with worldwide offices in Taiwan, Japan, Singapore, China, Europe, Hong Kong, India, and Korea. Visit our web site at https://www.lumissil.com
About Integrated Silicon Solution, Inc. (ISSI)
ISSI is a fabless semiconductor company that designs, develops and markets high performance SRAM, DRAM, Flash memory (including NOR flash, NAND flash and managed NAND solutions (eMMC)), and Analog/Mixed-signal integrated circuits. ISSI provides high-quality semiconductor products and has been a committed long-term supplier to its customers. ISSI is headquartered in Silicon Valley with worldwide offices in Taiwan, Japan, Singapore, China, Europe, Hong Kong, India, and Korea. Visit our web site at http://www.issi.com/
Contact: Raphi Zadicario, rzadicario@lumissil.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Miltenyi Biomedicine7.12.2025 23:30:00 CET | Press release
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
Genmab A/S7.12.2025 13:50:00 CET | Press release
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
SALI7.12.2025 02:14:21 CET | Press release
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
Evaxion6.12.2025 20:00:00 CET | Press release
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
Genmab A/S6.12.2025 15:30:00 CET | Press release
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
